Dominik Witzigmann

Dominik Witzigmann

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Dominik Witzigmann

NanoMedicines Innovation Network, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
AWAndreas Wicki
Andreas Wicki
DWDominik Witzigmann
Dominik Witzigmann
VBVimalkumar Balasubramanian
Vimalkumar Balasubramanian
JHJoerg Huwyler
Joerg Huwyler

4 December 2019 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
AAAkin Akinc
Akin Akinc
MMMartin A. Maier
Martin A. Maier
MMMuthiah Manoharan
Muthiah Manoharan
KFKevin Fitzgerald
Kevin Fitzgerald
MJMuthusamy Jayaraman
Muthusamy Jayaraman
PCPieter Cullis
Pieter Cullis

31 May 2021 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
JKJayesh A. Kulkarni
Jayesh A. Kulkarni
DWDominik Witzigmann
Dominik Witzigmann
STSarah B. Thomson
Sarah B. Thomson
SCSam Chen
Sam Chen
BLBlair R. Leavitt
Blair R. Leavitt
RMRoy van der Meel
Roy van der Meel
The increasing number of approved nucleic acid therapeutics demonstrates the potential to treat diseases by targeting their genetic blueprints in vivo. Conventional treatments generally induce therapeutic effects that are transient because they target proteins rather than underlying causes. In contrast, nucleic acid therapeutics can achieve long-lasting or even curative effects via gene inhibition, addition, replacement or editing. Their clinical translation, however, depends on delivery technologies that improve stability, facilitate internalization and increase target affinity. Here, we review four platform technologies that have enabled the clinical translation of nucleic acid therapeutics: antisense oligonucleotides, ligand-modified small interfering RNA conjugates, lipid nanoparticles and adeno-associated virus vectors. For each platform, we discuss the current state-of-the-art clinical approaches, explain the rationale behind its development, highlight technological aspects that facilitated clinical translation and provide an example of a clinically relevant genetic drug. In addition, we discuss how these technologies enable the development of cutting-edge genetic drugs, such as tissue-specific nucleic acid bioconjugates, messenger RNA and gene-editing therapeutics.

9 August 2019 in Accounts of Chemical Research
Verified
Journal Article
Closed access
JKJayesh A. Kulkarni
Jayesh A. Kulkarni
DWDominik Witzigmann
Dominik Witzigmann
SCSam Chen
Sam Chen
PCPieter Cullis
Pieter Cullis
RMRoy van der Meel
Roy van der Meel

12 November 2019 in Nanoscale
Verified
Journal Article
Closed access
PDF file
JKJayesh A. Kulkarni
Jayesh A. Kulkarni
DWDominik Witzigmann
Dominik Witzigmann
JLJerry Leung
Jerry Leung
YTYuen Yi C. Tam
Yuen Yi C. Tam
PCPieter Cullis
Pieter Cullis
In empty LNP formulations, DSPC–cholesterol resides in outer layers, whereas in loaded systems some of the DSPC–cholesterol is internalized together with siRNA.

19 May 2021 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
TRTanja Rothgangl
Tanja Rothgangl
MDMelissa K. Dennis
Melissa K. Dennis
PLPaulo J. C. Lin
Paulo J. C. Lin
RORurika Oka
Rurika Oka
DWDominik Witzigmann
Dominik Witzigmann
GSGerald Schwank
Gerald Schwank
Most known pathogenic point mutations in humans are C•G to T•A substitutions, which can be directly repaired by adenine base editors (ABEs). In this study, we investigated the efficacy and safety of ABEs in the livers of mice and cynomolgus macaques for the reduction of blood low-density lipoprotein (LDL) levels. Lipid nanoparticle–based delivery of mRNA encoding an ABE and a single-guide RNA targetingPCSK9, a negative regulator of LDL, induced up to 67% editing (on average, 61%) in mice and up to 34% editing (on average, 26%) in macaques. Plasma PCSK9 and LDL levels were stably reduced by 95% and 58% in mice and by 32% and 14% in macaques, respectively. ABE mRNA was cleared rapidly, and no off-target mutations in genomic DNA were found. Re-dosing in macaques did not increase editing, possibly owing to the detected humoral immune response to ABE upon treatment. These findings support further investigation of ABEs to treat patients with monogenic liver diseases.